Latest news with #DrReddy'sLaboratories
Mint
3 days ago
- Business
- Mint
Dr Reddy's Laboratories among four key stocks to trade Ex-dividend today
Dividend Stocks: Dr Reddy's Laboratories, LMW Ltd., Wheels India Limited, and Diffusion Engineers Limited remain among four key stocks that will trade Ex-dividend today July 10, 2025, was decided as the record date for identifying the list of qualified shareholders to receive the dividends that these companies had announced. In order for their names to appear on the list of eligible shareholders to receive the dividends, investors who wanted to receive dividends from these firms had to buy shares using the T+1 settlement method at least one day before the record date. Dr. Reddy's Laboratories Limited—The company had recommended a final dividend of Rs. 8/- per equity share of Rs. 1/- each for the financial year 2024-25 LMW Limited— The company had recommended a dividend of Rs. 30 per equity share with a face value of Rs. 10 each for the fiscal year ending March 31, 2025. The same, however, is subject to shareholder approval at the subsequent Annual General Meeting. Wheels India Limited—The Board of Wheel India had recommended a final dividend of Rs. 7.03 (70.3%) per equity share of Rs. 10/- each for the fiscal year that concluded on March 31, 2025, provided that the members of the company approve it at the subsequent AGM. If members approve the dividend, it will be paid by August 15, 2025, at the latest, as per the company. July 10, 2025, is the record date for the final dividend payment. Diffusion Engineers Limited—The Board of Diffusion Engineers had recommended a final dividend of Rs. 1.50 (one rupee fifty paisa only) on the equity shares of the company having a face value of Rs. 10/- each for the financial year 2024-25. The same translates into a dividend of 15.00% per equity share and is subject to approval of the shareholders at the ensuing Annual General Meeting. The dividend, if approved by the members of the Company at the ensuing Annual General Meeting ('AGM'), will be paid within 30 days from the date of AGM, as per the company Disclaimer: The views and recommendations made above are those of individual analysts or brokerage companies and not of Mint. We advise investors to check with certified experts before making any investment decisions.
&w=3840&q=100)
Business Standard
4 days ago
- Business
- Business Standard
Dividend stocks: These 4 stocks to go ex-date on July 10; are you eligible?
Dividend stocks today, Wednesday, July 9, 2025: Shares of Dr Reddy's Laboratories, LMW, Diffusion Engineers, and Wheels India are set to remain in focus following their announcements of dividend payouts for their shareholders. The BSE data suggest these stocks are scheduled to trade ex-dividend on Thursday, July 10, 2025. The ex-dividend date signifies the day from which a stock trades without the entitlement to the declared dividend. Thus, the investors must hold the shares prior to this date to qualify for the dividend. The companies, however, finalise the list of eligible shareholders based on their records as of the record date. Here are the complete list of the stocks trading ex-dividend on July 10, along with key details: Dr Reddy's Labs dividend 2025 Dr Reddy's Laboratories has announced that its board has recommended a final dividend of ₹8 per equity share of ₹1 each for the financial year 2024-25. The company has also fixed July 10, 2025, as the record date for the purpose of determining the members eligible to receive the final dividend for FY25. LMW dividend 2025 Industrial products maker company has informed the exchanges that its board has recommended a dividend of ₹30 per equity share having face value of ₹10 each for FY25. This, however, remains subject to the approval of the shareholders at the ensuing Annual General Meeting to be held on July 17, 2025. The company has also fixed July 10, 2025, as the record date for the purpose of determining the members eligible to receive the final dividend. Wheels India dividend 2025 Auto components & equipment maker company has announced that its board has recommended a final dividend of ₹7.03 (70.3 per cent) per equity share of ₹10 each for the year ended March 31, 2025, subject to approval of the members of the company at the ensuing AGM. The dividend, if approved by the members, shall be paid on or before August 15, 2025. The record date for the payment of the final dividend is July 10, 2025. Diffusion Engineers dividend 2025 Diffusion Engineers' board has recommended a final dividend of ₹1.50 per share on the equity shares of the company (i.e., dividend @ 15 per cent per equity share having face value of ₹10 each) for FY25, subject to approval of the shareholders at the ensuing Annual General Meeting to be held on Tuesday, July 22, 2025. The dividend, if approved by the members of the company at the ensuing AGM, will be paid within 30 days from the date of AGM. Diffusion Engineers has also fixed July 10, 2025, as the record date for the purpose of determining the members eligible to receive the final dividend for FY25. Besides these, shares of Pfizer, Mphasis, Elegant Marbles & Grani Industries, Johnson Controls-Hitachi Air Conditioning India, Kabra Extrusiontechnik, S.J.S. Enterprises, SML Isuzu, and Sundaram Finance will also remain in focus as they trade ex-dividend today.
Time of India
4 days ago
- Business
- Time of India
Dr. Reddy's Laboratories shares to go ex-dividend tomorrow. Do you own?
Shares of Dr Reddy's Laboratories are in focus on Wednesday, July 9, as today marks the last trading day for investors to buy the stock in order to qualify for the company's final dividend of Rs 8 per share for the financial year ended March 31, 2024 (FY25). The pharmaceutical major had earlier announced a final dividend of Rs 8 per equity share of face value Re 1 each. 'We would like to inform you that the Board of Directors of the Company, at their meeting held on May 9, 2025, has inter alia transacted and approved the following businesses: Recommended a final dividend of Rs. 8/- per equity share of Rs. 1/- each for the financial year 2024-25,' the company said in a previous filing to the stock exchanges. The record date for the dividend has been set as Wednesday, July 10, 2025. This means that investors who want to receive the dividend must purchase the shares before the ex-dividend date , which is today. Under standard settlement timelines followed by Indian stock exchanges, trades take two working days (T+1) to settle. Therefore, only those shareholders whose names appear in the company's register of members as of the record date — July 10 — will be eligible to receive the dividend. Live Events To ensure that the shares are credited in time, investors must buy Dr Reddy's shares no later than July 9. Therefore, investors eyeing the dividend benefit must ensure to complete their purchase of Dr Reddy's shares before the market closes today. The shares of Dr. Reddy's Laboratories closed 2% lower at Rs 1,283.90 on the BSE on Tuesday. ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Economic Times
4 days ago
- Business
- Economic Times
Dr. Reddy's Laboratories shares to go ex-dividend tomorrow. Do you own?
Shares of Dr Reddy's Laboratories are in focus on Wednesday, July 9, as today marks the last trading day for investors to buy the stock in order to qualify for the company's final dividend of Rs 8 per share for the financial year ended March 31, 2024 (FY25). ADVERTISEMENT The pharmaceutical major had earlier announced a final dividend of Rs 8 per equity share of face value Re 1 each. 'We would like to inform you that the Board of Directors of the Company, at their meeting held on May 9, 2025, has inter alia transacted and approved the following businesses: Recommended a final dividend of Rs. 8/- per equity share of Rs. 1/- each for the financial year 2024-25,' the company said in a previous filing to the stock exchanges. The record date for the dividend has been set as Wednesday, July 10, 2025. This means that investors who want to receive the dividend must purchase the shares before the ex-dividend date, which is standard settlement timelines followed by Indian stock exchanges, trades take two working days (T+1) to settle. Therefore, only those shareholders whose names appear in the company's register of members as of the record date — July 10 — will be eligible to receive the ensure that the shares are credited in time, investors must buy Dr Reddy's shares no later than July 9. Therefore, investors eyeing the dividend benefit must ensure to complete their purchase of Dr Reddy's shares before the market closes today. ADVERTISEMENT The shares of Dr. Reddy's Laboratories closed 2% lower at Rs 1,283.90 on the BSE on Tuesday. (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times) ADVERTISEMENT (You can now subscribe to our ETMarkets WhatsApp channel)
Indian Express
06-06-2025
- Business
- Indian Express
UP govt's ‘fully state-funded pharma park' invites centres from Gujarat pharma industry
A delegation from the Uttar Pradesh government, visiting Ahmedabad on Friday to promote its upcoming Bulk Drug Pharma Park in UP's Lalitpur district, announced that five companies, including Bharat Biotech and Dr Reddy's Laboratories, have already been allocated land and begun to set up their units. In total, 26 companies have expressed interest, including NATCO Pharma, Vins Bioproducts Ltd, and Rockwell Industries Ltd. The outreach event was held in collaboration with the Confederation of Indian Industry (CII). Mayur Maheshwari, CEO of the Uttar Pradesh State Industrial Development Authority (UPSIDA) and an IAS officer, addressed industry stakeholders and highlighted the park's strategic importance in reducing India's dependence on China for bulk drug production. Appealing directly to the Gujarat pharma industry, he said, 'We've come to Ahmedabad, which has shown the way for India. We request you to set up a parallel centre (in UP). We are more than ready to welcome you with open arms and we hope to match and provide even better facilities…' 'We have had this vacuum of bulk drugs and formulation in India. About 60% of Active Pharmaceutical Ingredients (APIs) are imported from China. This dependence is not only strategic, but it is a challenge to our entrepreneurs. If China can do it, why not UP and the rest of India?' Maheshwari said. During an interaction with the press, Maheshwari said that Gujarat was an important link for the Bulk Drug Pharma Park for its connectivity to the ports. Invoking cultural and spiritual references, Maheshwari said, 'This is the land of Shri Ram, Shri Krishna and Shri Buddha. When these three powers are present in a state, in a country, there can only be prosperity.' He praised the Yogi Adityanath-led government's leadership, citing the 'successful' hosting of the Mahakumbh, where 67 crore people had the opportunity to take the holy dip and that it 'went very well'. 'This is the first completely state-funded pharma park. All the money is from the UP government. We don't need to approach the Centre. Himachal Pradesh got a bulk drug pharma park in 2020-21 which is a non starter. In Andhra Pradesh, it has been four years and it is still just starting out… For allocation of resources and funding, we will do this on our own, which has not been possible even in Andhra and Gujarat,' said Maheshwari. When asked about skilled manpower by a stakeholder, Maheshwari said, 'We have developed a Promote Pharma initiative, which is a Section 8 company to strengthen and develop capacity building. It will invite the best professionals and will have industry, academia and govt linkage. Need-based professionals will come from there. We are also trying to get a National Institute of Pharmaceutical Education and Research (NIPER) in UP, to add to this ecosystem.' The Bulk Drug Pharma Park is coming up in Lalitpur district, located near the geographic centre of India. Delegation members highlighted that Uttar Pradesh has 14 airports, six of them international, and a dedicated helipad is also planned within the park. Additionally, both the Eastern and Western dedicated Railway Freight Corridors pass through the state, further strengthening connectivity. In the first phase, the UP government is developing 352 acres of the park. Officials said that 1,500 acre were already available for future expansion and that the park can be scaled up to 5,000 acres if needed. Maheshwari said, 'Lalitpur was also chosen because it is important to avail environmental clearance (EC) for the bulk drug and API industries. This place has less habitation. We have already got the EC. Masterplan is also approved and facility building work is already underway.' Of the park's total area, 67% is reserved for industry, 13% for green spaces, and the rest for support infrastructure and common facilities. Comparing it to other pharma parks in other states, Maheshwari said, 'We have lab testing, R&D incubation facilities, common climate controlled warehouses and technical regulatory support. We have these facilities which are missing in other places like Genome Park in Telangana and Jawaharlal Nehru Pharma City in Vizag of Andhra Pradesh.' On land pricing, he explained, 'We are giving land on a 90 year lease at Rs 75-77 lakh per acre but those setting up anchor units on 35-50 acre land will get 10% more discount. Basically, it is at Rs 1,700 per square metre of land for anchor units and Rs 1,914 per square metre for normal units. There is a 2% additional waiver if you make a full one-time payment.' Maheshwari said the park's incentives fall under the UP Pharma and Medical Devices Policy 2023 and include capital and interest subsidies, stamp duty exemption, patent and clinical trial support, a 10-year electricity duty waiver, and subsidies for quality certifications. Asked when companies can start operations, Maheshwari said, 'Right now.'
